Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
CNY 8.9
(-0.45%)
CNY 8.9
(-0.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -59 Million CNY | -93.5% |
| 2022 | 1.01 Billion CNY | 197.29% |
| 2021 | 392.49 Million CNY | 60.85% |
| 2020 | 215.63 Million CNY | 23.45% |
| 2019 | 175.2 Million CNY | -11.45% |
| 2018 | 148.5 Million CNY | 304.3% |
| 2017 | 37.4 Million CNY | -49.12% |
| 2016 | 109.87 Million CNY | -14.58% |
| 2015 | 128.63 Million CNY | 14.89% |
| 2014 | 108.2 Million CNY | -6.22% |
| 2013 | 117.48 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 30.66 Million CNY | 136.89% |
| 2024 Q3 | -73.44 Million CNY | -301.92% |
| 2024 Q1 | 30.1 Million CNY | 110.11% |
| 2023 Q2 | 15.95 Million CNY | -72.75% |
| 2023 Q3 | 13.98 Million CNY | -12.38% |
| 2023 FY | - CNY | -93.5% |
| 2023 Q4 | -77.06 Million CNY | -651.22% |
| 2023 Q1 | 58.55 Million CNY | -67.7% |
| 2022 Q2 | 368.58 Million CNY | 30.74% |
| 2022 Q1 | 281.92 Million CNY | 450.06% |
| 2022 FY | - CNY | 197.29% |
| 2022 Q4 | 181.29 Million CNY | -33.22% |
| 2022 Q3 | 271.46 Million CNY | -26.35% |
| 2021 Q3 | 127.66 Million CNY | 161.76% |
| 2021 Q4 | 51.25 Million CNY | -59.85% |
| 2021 Q1 | 356.39 Million CNY | 152.68% |
| 2021 Q2 | -206.72 Million CNY | -158.0% |
| 2021 FY | - CNY | 60.85% |
| 2020 Q4 | -676.59 Million CNY | -187.04% |
| 2020 FY | - CNY | 23.45% |
| 2020 Q3 | 777.35 Million CNY | 1166.03% |
| 2020 Q2 | -72.92 Million CNY | -145.78% |
| 2020 Q1 | 159.28 Million CNY | 122.87% |
| 2019 FY | - CNY | -11.45% |
| 2019 Q4 | -696.48 Million CNY | 0.0% |
| 2018 FY | - CNY | 304.3% |
| 2017 Q1 | 38.2 Million CNY | 100.45% |
| 2017 Q2 | 38.2 Million CNY | 0.0% |
| 2017 FY | - CNY | -49.12% |
| 2016 Q3 | 19.05 Million CNY | -46.88% |
| 2016 Q4 | 19.05 Million CNY | 0.0% |
| 2016 FY | - CNY | -14.58% |
| 2016 Q1 | 35.87 Million CNY | -11.8% |
| 2016 Q2 | 35.87 Million CNY | -0.0% |
| 2015 FY | - CNY | 14.89% |
| 2015 Q1 | 23.63 Million CNY | 0.0% |
| 2015 Q3 | 40.67 Million CNY | 72.09% |
| 2015 Q4 | 40.67 Million CNY | 0.0% |
| 2015 Q2 | 23.63 Million CNY | -0.0% |
| 2014 FY | - CNY | -6.22% |
| 2013 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.86 Billion CNY | 103.172% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.84 Billion CNY | 102.073% |
| Dirui Industrial Co.,Ltd. | 288.83 Million CNY | 120.43% |
| Beijing Strong Biotechnologies, Inc. | 697.99 Million CNY | 108.454% |
| Medicalsystem Biotechnology Co., Ltd. | 475.01 Million CNY | 112.423% |
| Maccura Biotechnology Co.Ltd | 651.98 Million CNY | 109.051% |
| Guangzhou Wondfo Biotech Co.,Ltd | 859.12 Million CNY | 106.868% |
| Guangdong Hybribio Biotech Co.,Ltd. | 236.08 Million CNY | 124.995% |
| BGI Genomics Co., Ltd. | 714.86 Million CNY | 108.255% |
| Amoy Diagnostics Co., Ltd. | 352.59 Million CNY | 116.736% |